The 7 most recent market catalysts affecting $GENB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 12, 2026
Corporate Catalyst
Bearish
Impact 92
Generate Biomedicines Reports Third Quarter 2026 Financial Results
Generate Biomedicines reported a net loss of $87.657 million, a substantial increase from $65.207 million in Q3 2025. Concurrently, revenue plummeted by 56.2% to $4.220 million. Th…
Oct 14, 2026
Corporate Catalyst
Bullish
Impact 85
Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market
Generate Biomedicines (GENB) has entered a strategic collaboration with Zealand Pharma to develop AI-engineered protein therapies for obesity and metabolic diseases. This is a sign…
Oct 13, 2026
Corporate Catalyst
Bullish
Impact 75
Generate Biomedicines To Receive $30M Upfront, Up To $1.2B In Milestones And Tiered Royalties Under Zealand Pharma Collaboration
Generate Biomedicines (GENB) has secured a significant collaboration with Zealand Pharma (ZEAL), involving an upfront payment of $30 million and potential milestones up to $1.2 bil…
Oct 5, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor has reaffirmed a 'Buy' rating and a $30 price target for Generate Biomedicines. This action signals that the analyst's positive outlo…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterated a 'Buy' rating and a $30 price target for Generate Biomedicines (GENB). This action signals that the analyst firm maintain…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $30
HC Wainwright & Co. analyst Mitchell S. Kapoor has maintained a 'Buy' rating on Generate Biomedicines (GENB) and raised the price target from $25 to $30. This action signals contin…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 85
Generate Biomedicines Q2 EPS $(0.52) Beats $(0.57) Estimate, Sales $6.314M Miss $6.625M Estimate
Generate Biomedicines (GENB) released its Q2 earnings, showing a mixed performance. While the company managed to beat EPS estimates, reporting a loss of $(0.52) against an expected…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.